Qualifying Transaction – Aumento Capital Corporation

June 9, 2011

Paul Pathak and Alicia McKeag worked with Annidis Corporation (formerly Aumento Capital Corporation) to complete its qualifying transaction. The transaction press release is reproduced below.

 

June 9, 2011 –Toronto, Ontario – Annidis Corporation (formerly Aumento Capital Corporation) (the “Company”) (ATO.P-TSX Venture), a Capital Pool Company, is pleased to announce that it closed today its Qualifying Transaction (“QT”) involving the exchange of all of the issued and outstanding securities of Annidis Health Systems Corp., (“Annidis”) for securities of the Company on a 1.25 for 1 basis.  Pursuant to the QT, the Company issued 48,910,331 common shares, 8,758,191 share purchase warrants, 3,700,000 stock options, and reserved for issuance up to 1,590,909 common shares upon the conversion of approximately $700,000 worth of outstanding Annidis convertible debentures, in exchange for all of the issued and outstanding securities of Annidis.

The following individuals now serve on the Company’s board of directors: Gerald Slemko, Michael Mueller, Zeljko Ribaric, Michael Crowley, Rony Thomas, and Timothy McCunn.  The board has appointed Mr. Slemko to be Chief Executive Officer, and Brian Baker to be Chief Financial Officer.

Concurrently with the closing of the QT Annidis completed a private placement of 6,074,000 units, with Canaccord Genuity Corp. acting as agent, for gross proceeds of $3,037,000.  Each unit was priced at $0.50 and consisted of one common share and one half of one share purchase warrant, each whole warrant entitling the holder to acquire one additional common share at an exercise price of $1.00 expiring on June 9, 2013.  Annidis also issued broker warrants to the agent entitling the holder to acquire 485,920 units at an exercise price of $0.50 per unit for a 24 month period, such units having the same terms as described above.  All securities issued in connection with the private placement were also exchanged for securities of the Company on a 1.25 for 1 basis.

Proceeds from the private placement will be used to fund working capital, to continue research and development efforts, to further sales and marketing activities for the Company’s multi-spectral digital ophthalmoscope, the Annidis RHATM, and to pay for Annidis’ costs of the QT.

The Company anticipates receiving its Final Exchange Bulletin from the TSX Venture Exchange in respect of the closing of the QT within the next week, at which time its common shares will resume trading under the symbol “RHA”, and it will no longer be considered a Capital Pool Company.  The Company has changed its name to “Annidis Corporation” as a result of the QT, and as approved by the shareholders of the Company at its last annual general and special meeting of shareholders.

For further information about the Company, please contact Gerald Slemko, Chief Executive Officer.

 

Neither TSX Venture Exchange Inc. nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Corporate, S. Paul Pathak, Transaction Press Releases